Eribulin plus trastuzumab in pretreated HER2-positive advanced breast cancer patients: safety and efficacy. An Italian experience
E.S. Lutrino(Ospedale A. Perrino), Saverio Cinieri(Ospedale A. Perrino), Claudio Zamagni(Policlinico S.Orsola-Malpighi), Pasqualinda Ferrara(Ospedale A. Perrino), Gianfranco Filippelli(Presidio Ospedaliero), Antonella Marino(University of Palermo), Palma Fedele(Ospedale A. Perrino), Marianna Giampaglia(Ospedale San Carlo), Chiara Caliolo(Ospedale A. Perrino), Antonio Febbraro(Fatebenefratelli Hospital), Nicola Calvani(Ospedale A. Perrino), Anna Maria Quaranta(Ospedale A. Perrino), Domenico Bilancia(Azienda Ospedaliera Ospedale San Carlo Borromeo), Laura Orlando, Caterina Fontanella(Centro di Riferimento Oncologico), Daniela Rubino(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Claudio Scavelli(Gallipoli Medical Research Foundation), Paola Schiavone(Ospedale A. Perrino), Guido Giordano(University of Foggia)
Cited by 6
Related Papers
Gemcitabine Plus Vinorelbine Versus Vinorelbine Alone in Elderly Patients With Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2000|452
Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study
|Journal of Clinical Oncology|2012|368
First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial
|Journal of Clinical Oncology|2012|234